C4 Therapeutics, Inc.

NASDAQ:CCCC

Biotechnology

Healthcare
$2.48 +2.06%

+$0.08 today

Market cap
$325.01M
Beta
2.93
P/E (TTM)
-4.9
EPS (TTM)
-$0.82
52W Low $1.36High $4.60

Volume 2.75M

Average 2.76M

CCCC Capital Expenditures

Cash spent on property, plant, equipment, and other long-term assets.

C4 Therapeutics, Inc.NASDAQ: CCCC

Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026

Capital expenditures turns negative

Q1 FY2026 capital expenditures was -$64K, compared with $0 a year earlier. Trailing-twelve-month capital expenditures was -$671K. Over 3 fiscal years it compounded at -52.0% a year.

Context

  • Capital expenditures amounted to 1.7% of revenue in FY2025, up 1.2 pp from a year earlier.
  • Capital expenditures grew in size in 1 of the last 3 fiscal years.

What to watch

Whether quarterly capital expenditures holds near -$64K or moves back toward the trailing-twelve-month quarterly average of -$167.75K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$64K+481.8% QoQ
Last fiscal yearDec 2025
-$607K+237.2% YoY
LTMMar 2026
-$671K+272.8% YoY
Capital Expenditures past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+237.2%——
3-year CAGR-52.0%——
5-year CAGR——
10-year CAGR——

Capital Expenditures history

USD · from the cash flow

Latest · FY2025
(607K) USD
Year-over-year change
-237.2%

Capital Expenditures vs competitors

How CCCC compares with its peers on the latest reported figures

  • Peers report in different currencies, so capital expenditures is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +272.8% is the 2nd highest of 9, against a peer median of -55.9%.
  • Capital expenditures amounts to 1.9% of revenue for CCCC, versus a peer median of 4.1%.
CCCC Competitors
Capital Expenditures for CCCC and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$3.49M USD+602.4%-9.8%179.1%
CDXSCodexis, Inc.LTM Mar 2026$3.39M USD-23.5%-18.7%4.3%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$671K USD+272.8%-52.0%1.9%
OABIOmniAb, Inc.LTM Mar 2026$523K USD-54.8%-68.0%1.8%
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$506K USD-70.7%-37.4%17.1%
MOLNMolecular Partners AGLTM Mar 2026CHF 333.55K CHF-67.9%-20.4%—
PEPGPepGen Inc.LTM Mar 2026$139K USD-75.6%-58.7%—
SGMOSangamo Therapeutics, Inc.LTM Mar 2026$115K USD-56.9%-82.8%0.3%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$68.98K USD+76.9%+3.5%3.9%
Peer median (excluding CCCC) —-55.9%-28.9%4.1%

Competitors are the stored peer set for CCCC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(83.89M)(128.18M)(132.49M)(105.32M)(104.99M)
Depreciation & Amortization1.49M1.68M1.88M1.82M1.96M
Deferred Income Tax1.88M0000
Stock-Based Compensation21.51M30.02M27.24M29.66M19.1M
Change in Working Capital(30.09M)(16.78M)(6.94M)7.65M(29.28M)
Accounts Receivables(1.23M)4.24M(10.33M)8.7M701K
Inventory(2.63M)0000
Accounts Payables(1.18M)(3.33M)273K(119K)(468K)
Other Working Capital(25.05M)(17.69M)3.12M(930K)(29.52M)
Other Non-Cash Items2.13M7.32M3.48M1.03M14.52M
Operating Cash Flow(86.97M)(105.94M)(106.84M)(65.16M)(98.69M)
Capital Expenditures(1.28M)(5.5M)(1.71M)(180K)(607K)
Acquisitions (Net)188.06M(63.92M)000
Purchases of Investments(537.74M)(219.53M)(129.9M)(284.32M)(227.07M)
Sales of Investments349.68M283.45M289.96M233.23M219.08M
Other Investing Activities(188.06M)63.92M000
Investing Cash Flow(189.34M)58.42M158.35M(51.27M)(8.6M)
Debt Repayment00(12.5M)00
Common Stock Issued169.47M777K57.67M44.37M126.32M
Common Stock Repurchased00(110K)(194K)(193K)
Dividends Paid00000
Other Financing Activities1.94M370K426K1.16M274K
Financing Cash Flow171.4M1.15M45.49M45.34M126.4M
Effect of Forex Changes00000
Net Change in Cash(104.9M)(46.37M)97M(71.09M)19.1M
Free Cash Flow(88.24M)(111.44M)(108.55M)(65.34M)(99.3M)

C4 Therapeutics, Inc.

NASDAQ:CCCC

Intrinsic Alpha fair value

Locked

Current Price

$2.48

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.